Core Insights - The event "Multinational Pharmaceutical Enterprises Shunyi Action" aimed to optimize the import pathways for urgently needed and rare disease drugs, gathering over 200 participants from government, medical institutions, and multinational pharmaceutical companies to discuss new facilitation measures [1] Group 1: Policy and Regulatory Framework - Experts from various organizations shared insights on the import of rare disease and urgently needed drugs, focusing on drug application, expert evaluation, and pharmaceutical service models to enhance drug accessibility and affordability [3] - The Beijing Municipal Medical Insurance Bureau and other departments introduced new policies supporting the high-quality development of innovative drugs and measures for customs facilitation at Tianzhu Port [3] Group 2: Innovative Practices and Achievements - The Capital Airport Economic Zone has implemented a "white list system, bonded stockpiling, phased exit from the zone, and full traceability" model to facilitate the clinical use of urgently needed drugs that are available abroad but not yet in China [3] - The policy for the rare disease drug guarantee zone has created a fast track for the import of urgently needed rare disease drugs, transforming the situation from "people waiting for drugs" to "drugs waiting for people" [5] Group 3: Industry Growth and Economic Impact - The Shunyi District has prioritized the pharmaceutical and health industry, aiming for an overall industry scale of 69.1 billion by 2025, with an average annual growth rate of 17.4% over three consecutive years [5] - Tianzhu Comprehensive Bonded Zone's pharmaceutical trade has exceeded 100 billion for three consecutive years, accounting for nearly one-third of the national total, solidifying its position as the largest pharmaceutical trade port in China [5] Group 4: Future Directions and Strategic Initiatives - The release of the first special support policy for the pharmaceutical health industry in Shunyi District is expected to strengthen its hub position in pharmaceutical trade and attract multinational pharmaceutical companies to establish R&D and supply chain operations [6]

Core Insights - The Beijing Tianzhu Comprehensive Bonded Zone achieved a total import and export value of 109.23 billion yuan from January to November 2025, maintaining a stable scale above 100 billion yuan for three consecutive years [1] - The import value reached 105.06 billion yuan, while the export value was 4.17 billion yuan, with significant growth in cross-border pharmaceutical trade, particularly non-vaccine drug imports, which amounted to approximately 82.395 billion yuan, reflecting a year-on-year increase of 27.47% [1] Group 1: Pharmaceutical Trade Highlights - The import of rare disease drugs in the Tianzhu Comprehensive Bonded Zone was particularly noteworthy, with an import value of 3.16 billion yuan from January to October 2025, marking an 83% increase and accounting for 97% of the rare disease drug imports in Beijing during the same period [3] - The growth in rare disease drug imports is attributed to a policy initiative from the State Council at the end of 2023, which supported the establishment of a rare disease drug guarantee pilot zone in Tianzhu [3] - The Tianzhu zone has established a "white list" of first batch import enterprises, facilitating the import of specialized drugs and enhancing operational efficiency [3] Group 2: Operational Efficiency and Growth - The Tianzhu Comprehensive Bonded Zone has implemented various innovative measures to optimize the business environment, such as multiple declarations for a single customs clearance and intelligent management at checkpoints, which have significantly improved trade efficiency [4] - The import scale of medical products in the zone has grown from 24.9 billion yuan in 2019 to 47.5 billion yuan in 2025, demonstrating substantial business growth [4] - Cultural trade has emerged as a new growth point, with cultural product import and export value exceeding 200 million yuan in the first three quarters, reflecting a year-on-year increase of 140% [4] Group 3: Future Development Plans - The Tianzhu Comprehensive Bonded Zone plans to leverage the establishment of the rare disease drug guarantee pilot zone to further enhance policy advantages and promote high-level institutional openness [5] - The focus will be on optimizing the international service environment to support high-quality development of the air economy [5]